Genise Binns
Psychiatric/Mental Health · Virginia Beach, VANPI 1154989408
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,406 of the $12,307 with a category attached, or 84.6%. It is spread thinly across 22 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $5,109 and has fallen 56.1% since, to $2,241 in 2025. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $30.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- AbbVie$2K
- Neuronetics, Inc.$1K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$926
- Teva Pharmaceuticals USA, Inc.$813
- plus $4K from 16 others
What the payments were for
- Travel & lodging$1,79715%
- Food & beverage$10,40685%
- Education$1031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 29 | $2,166 |
| AbbVie | 71 | $1,555 |
| Neuronetics, Inc. | 6 | $1,397 |
| Alkermes, Inc. | 37 | $1,000 |
| Neurocrine Biosciences, Inc. | 35 | $926 |
| Teva Pharmaceuticals USA, Inc. | 40 | $813 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $771 |
| Otsuka America Pharmaceutical, Inc. | 28 | $593 |
| Vanda Pharmaceuticals Inc. | 19 | $549 |
| E.r. Squibb & Sons, L.L.C. | 23 | $531 |
| Axsome Therapeutics, Inc. | 12 | $445 |
| Supernus Pharmaceuticals, Inc. | 15 | $307 |
| Sunovion Pharmaceuticals Inc. | 11 | $253 |
| Tris Pharma Inc | 9 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $224 |
| Lundbeck LLC | 12 | $196 |
| Corium, LLC | 4 | $171 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Noven Therapeutics, LLC | 3 | $41 |
| Harmony Biosciences LLC | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $24 |
| Bausch Health US, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,452
- NEUROSTAR TMS THERAPY SYSTEM$1,319
- LYBALVI$980
- VRAYLAR$567
- ARISTADA$471
- CAPLYTA$378
- INGREZZA$376
- Austedo XR$249
- COBENFY$248
- Auvelity$237
- INVEGA SUSTENNA$129
- LATUDA$123
- Quillichew ER$120
- Quillivant$120
- Dyanavel XR$120
- ARISTADA INITIO$118
- Azstarys$116
- Fanapt$116
- REXULTI$108
- QELBREE$105
How this compares
$12,307 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $102,617 |
| Abilify MaintenaAripiprazole | 11 | $25,588 |
| Quetiapine Fumarate | 25 | $826 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 24 | $425 |
| Duloxetine Hcl | 21 | $401 |
| Bupropion XlBupropion Hcl | 17 | $390 |
| Aripiprazole | 24 | $368 |
| Hydroxyzine Hcl | 14 | $348 |
| Sertraline Hcl | 24 | $323 |
| Buspirone Hcl | 39 | $290 |
| Trazodone Hcl | 20 | $258 |
| Risperidone | 20 | $254 |
| Alprazolam ErAlprazolam | 13 | $223 |
| Lamotrigine | 31 | $201 |
| Hydroxyzine Pamoate | 20 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $926 | $102,61713 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $593 | $25,58811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Virginia Beach
- Mary CrutchfieldVirginia Beach$8K
- Edward EvardVirginia Beach$8K
- Trisha ParkerVirginia Beach$6K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
- Christine GilmoreBedford$75K
- Sarah FaberNewport News$59K
- Kristine GarciaGlen Allen$46K
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.